Subscribe to Newsletter

Professional Development

Business & Profession Professional Development

Quality Family Time at a Congress

| Nicole Kretz

Grasp the opportunity to take the whole family to conference locations – and gain a new perspective on the places you visit.

Business & Profession Cataract

Selecting for Patient Success

| Alain Saad

Using the best diagnostic tools will help ensure that the right procedures are selected for patients, driving improvements in outcomes for refractive surgery

Business & Profession Professional Development

The Power of the List

| Richard Gallagher

The Ophthalmologist Power List 2014 is this publication’s catalog of the 100 most influential people in ophthalmology today.

Business & Profession Professional Development

World Travel for a Write up of Your Work

| Mark Hillen

If you’re a retina specialist, you’ll be more likely than not to see patients with diabetic macular edema (DME) on a daily basis. Lasers and anti-VEGF therapy have transformed outcomes within a generation

Business & Profession Professional Development

Top Tips for Travellers

| Andy Davies

Attending conferences, making presentations and sitting on committees is part and parcel of the job for leading ophthalmologists. Here are my tips to make sure you arrive fresh and look the part.

Business & Profession Professional Development

Championing the Will of Wills

Sitting down with Julia Haller, Ophthalmologist-in-Chief, and Joseph Bilson, Chief Executive Officer of the Wills Eye Hospital, Philadelphia, PA, USA.

Business & Profession Professional Development

How to Improve Visual Acuity Testing

| Florian Kretz

The Salzburg Reading Desk is one promising approach to standardizing visual assessments for multifocal intraocular lenses.

Business & Profession Professional Development

Why Snellen Must Die

| Mark Blecher

For the sake of our patients and our profession, we need to improve upon the nineteenth-century pictograms that are currently used for visual assessment.

Business & Profession Professional Development

Business in Brief

| Mark Hillen

Aflibercept gets approved by NICE, STAAR’s Visian ICL with CentraFLOW gets approved in Japan, and rises and falls in Allergan and Alcon’s revenues.

Business & Profession Professional Development

Big in Japan

| Mark Hillen

Acucela prices its initial public offering on the Tokyo Stock Exchange at $162M.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer element

This new disclaimer element is now part of all brands. It is editable on the start page and will be shown on all pages

Once confirmed we store a cookie to not show the disclaimer again.